Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CCND1 | P24385 | 20/20 | 1.00 |
| ▸ | CCNE1 | P24864 | 20/20 | 1.00 |
| ▸ | CDK2 | P24941 | 20/20 | 1.00 |
| ▸ | CDK6 | Q00534 | 20/20 | 1.00 |
| ▸ | CDK4 | P11802 | 7/20 | 1.00 |
| ▸ | CCND3 | P30281 | 6/20 | 1.00 |
| ▸ | CCNT1 | O60563 | 4/20 | 1.00 |
| ▸ | CDK9 | P50750 | 4/20 | 1.00 |
| ▸ | CCNE2 | O96020 | 1/20 | 1.00 |
| ▸ | RB1 | P06400 | 1/20 | 1.00 |
| ▸ | CDK1 | P06493 | 1/20 | 1.00 |
| ▸ | CCNA2 | P20248 | 1/20 | 1.00 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Ebvaciclib SCHEMBL19863683 | 1.00 | CCND1 (1.00) | CCND1CCNE1CDK2CDK6CDK4 | |
| Ebvaciclib SCHEMBL30550182 | 1.00 | CCND1 (1.00) | CCND1CCNE1CDK2CDK6CDK4 | |
| Ebvaciclib SCHEMBL19880088 | 1.00 | CCND1 (1.00) | CCND1CCNE1CDK2CDK6CDK4 | |
| Ebvaciclib SCHEMBL29359734 | 1.00 | CCND1 (1.00) | CCND1CCNE1CDK2CDK6CDK4 | |
| SCHEMBL24373406 | 0.98 | CCND1 (0.95) | CCND1CCNE1CDK2CDK6CDK4 | |
| Ebvaciclib SCHEMBL30550073 | 0.94 | CCND1 (0.89) | CCND1CCNE1CDK2CDK6CDK4 | |
| Ebvaciclib SCHEMBL30550154 | 0.94 | CCND1 (0.89) | CCND1CCNE1CDK2CDK6CDK4 | |
| Ebvaciclib SCHEMBL30550079 | 0.94 | CCND1 (0.89) | CCND1CCNE1CDK2CDK6CDK4 | |
| Ebvaciclib SCHEMBL30550180 | 0.94 | CCND1 (0.88) | CCND1CCNE1CDK2CDK6CDK4 | |
| SCHEMBL19863694 | 0.93 | CCND1 (1.00) | CCND1CCNE1CDK2CDK6CDK4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 679 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2026101937-A1 | COMPOSITIONS COMPRISING (Z)-ENDOXIFEN AND A CDK4/6 INHIBITOR AND METHODS OF USE THEREOF | ATOSSA THERAPEUTICS, INC. (US) | 2026-05-15 | — | — | WO | claimed |
| EP-4683635-A1 | USES OF A CHECKPOINT KINASE 1 (CHK1) INHIBITOR | Boundless Bio, Inc. (US) | 2026-01-28 | — | — | EP | claimed |
| US-20250381202-A1 | PRODRUG KIT FOR MULTI-PRONGED CHEMOTHERAPY | ZOUNEK ALEX (DE) | 2025-12-18 | — | — | US | claimed |
| WO-2025215042-A1 | COMBINATIONS OF A CALCIUM HOMEOSTASIS DISRUPTOR WITH A DEATH RECEPTOR 5 AGONIST FOR TREATING CANCER | STICHTING HET NEDERLANDS KANKER INSTITUUT - ANTONI VAN LEEUWENHOEK ZIEKENHUIS (NL) | 2025-10-16 | — | — | WO | claimed |
| EP-4631501-A1 | COMBINATIONS OF A CALCIUM HOMEOSTASIS DISRUPTOR WITH A DEATH RECEPTOR 5 AGONIST FOR TREATING CANCER | Stichting Het Nederlands Kanker Instituut- Antoni van Leeuwenhoek Ziekenhuis (NL) | 2025-10-15 | — | — | EP | claimed |
| WO-2025202647-A1 | CDK INHIBITORS CONJUGATED TO EGFR TARGETING MOIETIES | KING'S COLLEGE LONDON (GB) | 2025-10-02 | — | — | WO | claimed |
| EP-4551565-A1 | PRODRUG KIT FOR MULTI-PRONGED CHEMOTHERAPY | Zounek, Alex (DE) | 2025-05-14 | — | — | EP | claimed |
| EP-4066823-B1 | REDUCED CALORIC INTAKE AND ANTICANCER AGENTS FOR THE TREATMENT OF CANCER | IFOM ST FONDAZIONE DI ONCOLOGIA MOLECOLARE ETS (IT) | 2025-04-30 | — | — | EP | claimed |
| WO-2025051337-A1 | COMPOSITIONS AND METHODS FOR TREATING AND PREVENTING ORAL CANCER | Afyx Development A/S (DK) | 2025-03-13 | — | — | WO | claimed |
| US-20250073241-A1 | Combination Therapies Using PRMT5 Inhibitors for the Treatment of Cancer | Mirati Therapeutics, Inc. (US) | 2025-03-06 | — | — | US | claimed |
| US-20220040324-A1 | COMBINATION OF ANTIBODY-DRUG CONJUGATE AND KINASE INHIBITOR | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2022-02-10 | — | — | US | claimed |
| US-20210346384-A1 | COMBINATIONS OF TGF-BETA INHIBITORS AND CDK INHIBITORS FOR CANCER TREATMENTS | PFIZER INC. (US) | 2021-11-11 | — | — | US | claimed |
| WO-2021176349-A1 | COMBINATION OF AN ANAPLASTIC LYMPHOMA KINASE INHIBITOR AND A CYCLIN DEPENDENT KINASE INHIBITOR | PFIZER INC. (US) | 2021-09-10 | — | — | WO | claimed |
| EP-3852758-A1 | COMBINATIONS OF TGFB INHIBITORS AND CDK INHIBITORS FOR THE TREATMENT OF BREAST CANCER | Pfizer Inc. (US) | 2021-07-28 | — | — | EP | claimed |
| EP-3497103-B1 | PYRIDOPYRIMDINONE CDK2/4/6 INHIBITORS | PFIZER (US) | 2021-05-05 | — | — | EP | claimed |
| US-20200392142-A1 | CDK2/4/6 Inhibitors | PFIZER INC. (US) | 2020-12-17 | — | — | US | claimed |
| WO-2020239558-A1 | COMBINATION THERAPIES USING CDK INHIBITORS | PFIZER INC. (US) | 2020-12-03 | — | — | WO | claimed |
| WO-2020240360-A1 | COMBINATION THERAPIES USING CDK INHIBITORS | PFIZER INC. (US) | 2020-12-03 | — | — | WO | claimed |
| US-10800783-B2 | CDK2/4/6 inhibitors | PFIZER INC. (US) | 2020-10-13 | — | — | US | claimed |
| WO-2020058820-A1 | COMBINATIONS OF TGFB INHIBITORS AND CDK INHIBITORS FOR THE TREATMENT OF BREAST CANCER | PFIZER INC. (US) | 2020-03-26 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250381202-A1 | PRODRUG KIT FOR MULTI-PRONGED CHEMOTHERAPY | KIT, CTSL, PAICS | CCND1 256/4885CCNE1 125/4885CDK2 111/4885 |
| US-20200392142-A1 | CDK2/4/6 Inhibitors | CDK2, CDK6, CDK20 | CCND1 39/4885CCNE1 28/4885CDK2 1/4885 |
| US-10800783-B2 | CDK2/4/6 inhibitors | CDK2, CDK6, CDK20 | CCND1 40/4885CCNE1 29/4885CDK2 1/4885 |
| US-20220040324-A1 | COMBINATION OF ANTIBODY-DRUG CONJUGATE AND KINASE INHIBITOR | WEE1, ERBB3, ERBB2 | CCND1 356/4885CCNE1 22/4885CDK2 30/4885 |
| US-20250073241-A1 | Combination Therapies Using PRMT5 Inhibitors for the Treatment of Cancer | PRMT5, PRMT6, PRMT1 | CCND1 629/4885CCNE1 393/4885CDK2 65/4885 |
| US-20210346384-A1 | COMBINATIONS OF TGF-BETA INHIBITORS AND CDK INHIBITORS FOR CANCER TREATMENTS | CDK6, CDK3, CDK1 | CCND1 55/4885CCNE1 49/4885CDK2 10/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.